Drugs / DAW1033B2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03426631 | Sep 2017 → Oct 2019 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAW1033B2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03426631 ↗ |
| Route | Oral | “DAW1033B2 oral capsule” NCT03426631 ↗ |